IRIS Institutional Research Information System - OPENBS Open Archive UniBS

BERRUTI, ALFREDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.807
AS - Asia 13.181
EU - Europa 10.099
SA - Sud America 3.284
AF - Africa 255
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 18
Totale 57.669
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.447
SG - Singapore 4.731
CN - Cina 4.073
BR - Brasile 2.780
UA - Ucraina 2.757
HK - Hong Kong 1.763
DE - Germania 1.539
IT - Italia 1.288
PL - Polonia 948
VN - Vietnam 926
RU - Federazione Russa 692
GB - Regno Unito 637
FI - Finlandia 627
TR - Turchia 592
IE - Irlanda 515
IN - India 264
FR - Francia 228
AR - Argentina 202
EE - Estonia 191
BD - Bangladesh 177
CA - Canada 177
SE - Svezia 135
ID - Indonesia 133
CZ - Repubblica Ceca 113
MX - Messico 110
ZA - Sudafrica 105
IQ - Iraq 89
NL - Olanda 88
EC - Ecuador 85
JP - Giappone 80
ES - Italia 71
AT - Austria 63
BE - Belgio 53
SA - Arabia Saudita 50
PK - Pakistan 44
PY - Paraguay 43
VE - Venezuela 42
UZ - Uzbekistan 41
MA - Marocco 40
CO - Colombia 39
CL - Cile 37
AE - Emirati Arabi Uniti 30
EG - Egitto 28
LT - Lituania 24
KE - Kenya 23
AU - Australia 21
CH - Svizzera 21
KZ - Kazakistan 21
UY - Uruguay 21
DZ - Algeria 20
PE - Perù 20
AZ - Azerbaigian 19
JM - Giamaica 19
KR - Corea 17
EU - Europa 16
JO - Giordania 16
PT - Portogallo 15
LB - Libano 14
TN - Tunisia 14
AL - Albania 13
CR - Costa Rica 13
DK - Danimarca 13
IL - Israele 13
NP - Nepal 11
PA - Panama 11
BG - Bulgaria 10
BO - Bolivia 10
IR - Iran 10
RO - Romania 9
KG - Kirghizistan 8
LV - Lettonia 8
TT - Trinidad e Tobago 8
HN - Honduras 7
PS - Palestinian Territory 7
BB - Barbados 6
ET - Etiopia 6
TW - Taiwan 6
BH - Bahrain 5
DO - Repubblica Dominicana 5
HU - Ungheria 5
MU - Mauritius 5
NO - Norvegia 5
SK - Slovacchia (Repubblica Slovacca) 5
AM - Armenia 4
CY - Cipro 4
GE - Georgia 4
GR - Grecia 4
LK - Sri Lanka 4
MD - Moldavia 4
MK - Macedonia 4
OM - Oman 4
GY - Guiana 3
IS - Islanda 3
LA - Repubblica Popolare Democratica del Laos 3
MY - Malesia 3
NZ - Nuova Zelanda 3
PH - Filippine 3
SN - Senegal 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
Totale 57.632
Salva come PNG Salva come JPEG
Città #
Fairfield 4.232
Woodbridge 3.240
Ashburn 2.500
Houston 2.214
Singapore 2.108
Jacksonville 1.880
Hong Kong 1.756
Seattle 1.740
Cambridge 1.594
Wilmington 1.379
Ann Arbor 1.362
Beijing 1.201
Warsaw 937
Princeton 879
Chandler 728
New York 704
Los Angeles 572
Dallas 536
Chicago 492
Dublin 472
Nanjing 471
Istanbul 466
Helsinki 405
Ho Chi Minh City 323
Munich 301
The Dalles 301
Buffalo 250
Brescia 244
Des Moines 230
Redondo Beach 226
São Paulo 201
Dearborn 199
Moscow 198
Tallinn 191
Nanchang 188
Salt Lake City 188
San Diego 184
Hanoi 163
Shanghai 157
Changsha 151
Milan 144
Shenyang 140
Boardman 134
Hebei 133
San Francisco 131
London 120
Turku 116
Tianjin 101
Jinan 93
Rio de Janeiro 88
Tampa 86
Jakarta 85
Brno 80
Dong Ket 80
Elk Grove Village 80
Secaucus 72
Brooklyn 70
Nuremberg 70
Santa Clara 70
Jiaxing 69
Belo Horizonte 61
Dalmine 60
Stockholm 60
Hangzhou 58
Romola 57
Tokyo 57
Orange 56
Brasília 54
Johannesburg 54
Kunming 54
Verona 54
Brussels 52
Lancaster 52
Phoenix 52
Kocaeli 51
Poplar 49
Toronto 49
Zhengzhou 49
Atlanta 46
Rome 46
Boston 45
Guangzhou 44
Orem 43
Sterling 43
Curitiba 42
Montreal 41
Washington 40
Denver 38
Lappeenranta 38
Porto Alegre 38
West Jordan 38
Tashkent 37
Campinas 36
Haiphong 35
Chennai 34
Da Nang 34
Baghdad 33
Mexico City 33
Ningbo 33
Biên Hòa 32
Totale 39.353
Salva come PNG Salva come JPEG
Nome #
Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer 762
Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. 359
GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity 279
Adrenocortical carcinoma xenograft in zebrafish embryos as model to study the in vivo cytotoxicity of abiraterone acetate 276
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 254
Excess of second tumors in denosumab-treated patients: A metabolic hypothesis 233
Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma 231
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study 230
Eight‐week interval in flushing and locking port‐a‐cath in cancer patients: A single‐institution experience and systematic review 229
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. 224
In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures☆ 223
Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures 223
Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review 220
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† 219
Pros-IT CNR: an Italian prostate cancer monitoring project 205
IN VITRO ANTITUMOR ACTIVITY OF PROGESTERONE IN HUMAN ADRENOCORTICAL CARCINOMA 204
Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy 202
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 201
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case 198
Clinical and histological prognostic factors of recurrent and/or metastatic salivary gland adenoid cystic carcinoma 197
Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy 196
Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells 195
Immunotherapy failure in adrenocortical cancer: where next? 194
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials 193
Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma 192
Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy 191
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement 190
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. 184
The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma 181
Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity 177
Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells 176
Regression of advanced neuroendocrine tumors among patients receiving placebo 176
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents 176
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options 176
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 174
Should Adjuvant Weekly Paclitaxel Be Considered Less Efficacious Than Anthracyclines Plus Cyclophosphamide for Lower Risk Patients With Early-Stage Breast Cancer? 173
Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study 171
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines 169
Biological bases of radical prostatectomy in the management of prostate cancer patients with oligometastatic disease 169
Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy 169
Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria 169
Palbociclib inhibits proliferation of human adrenocortical tumor cells 168
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer 167
Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis 167
Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method 164
Management of Severe Cushing Syndrome Induced by Adrenocortical Carcinoma with Abiraterone Acetate: A Case Report 164
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer 163
Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies. 162
A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report 162
CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs) 161
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement 160
When should everolimus be administered in the natural history of pancreatic neuroendocrine tumors? 160
Adjuvant bisphosphonates in patients with breast cancer: Does the potency matter? 160
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 160
Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis 160
Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature 159
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) 158
Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. 158
828PBONE METASTASES FROM RCC ARE NOT ALWAYS ASSOCIATED WITH A POOR PROGNOSIS 158
Antineoplastic Activity of Artemisinin in Adrenocortical Carcinoma 158
The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients 157
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. 156
Osimertinib in EGFR Mutation–Positive Advanced NSCLC 156
Effect of primary letrozole treatment on tumor expression of mTOR and HIF-1α and relation to clinical response 156
Exemestane with ovarian suppression in premenopausal breast cancer. 156
Serum vitamin D and prostate cancer prognosis: The story continues 155
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature 155
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 155
Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice 153
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 152
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients 152
Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer? 151
A current perspective on treatment of adrenocortical carcinoma 151
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports 151
Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines? 151
5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma 147
Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients 147
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. 146
Gonadal function in male patients with metastatic renal cell cancer treated with sunitinib: Effects of testosterone replacement on quality of life. 146
Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge. 146
An unusual case of a well-differentiated neuroendocrine tumour of the ileum with peritoneal carcinomatosis: A case report 144
Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report 143
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma 143
Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy worse radical cystectomy outcomes in frails 143
Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference 143
Molecular target agents in adrenocortical carcinoma: rationale and difficulties in trial design 142
IFN-α in advanced well-differentiated neuroendocrine tumors: The neglected drug? 142
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 142
Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases. 139
MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects 139
The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures 138
Aspergillosis superinfection as a cause of death of crizotinib-induced interstitial lung disease successfully treated with high-dose corticosteroid therapy 137
Abiraterone and increased survival in metastatic prostate cancer 137
Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance 137
Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. 136
Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. 135
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study 135
Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study 135
Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): An European Network for the Study of Adrenal Tumor (ENSAT) study 134
The pathological diagnosis of neuroendocrine tumors: Common questions and tentative answers 134
Totale 17.846
Salva come PNG Salva come JPEG
Categoria #
all - tutte 291.262
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 291.262
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.783 0 0 0 0 0 777 392 786 619 1.174 650 385
2021/20223.503 274 702 93 213 50 182 214 234 194 349 267 731
2022/20232.586 497 83 74 178 191 712 10 212 347 44 115 123
2023/20243.948 180 96 316 217 207 696 109 145 1.039 118 48 777
2024/202510.895 98 74 98 1.510 1.168 737 591 293 1.088 803 2.697 1.738
2025/202611.285 1.636 2.770 1.934 3.138 1.553 254 0 0 0 0 0 0
Totale 58.681